The use of telemedicine, or remote clinical consultations, was limited in most OECD countries before the COVID-19 pandemic, held back by regulatory barriers and hesitancy from patients and providers. In early 2020, as COVID-19 massively disrupted in-person care, governments moved quickly to...

The use of telemedicine was quite limited in most OECD countries before the COVID-19 pandemic, held back by regulatory barriers and hesitancy from patients and providers. In early 2020, as COVID-19 massively disrupted in-person care, governments moved quickly to promote the use of telemedicine....

More than 35 million people worldwide had dementia in 2010, when annual costs were estimated at USD 604 billion; the number of people with dementia is expected to exceed 115 million by 2050. Alzheimer’s disease is today considered the prototype problem for the Grand Global Challenge in...

Science and technology improves human health but the pressure for faster and larger improvements is building with the continued ageing of the population of many OECD countries and the associated increased demands for health care. A fundamental starting point for better understanding of the...

This report examines examples of new and emerging governance models that aim to support the responsible development of diagnostics and treatments based on the latest advances in biomedicine. In particular, it presents programmes and initiatives that aim to manage uncertainty in the development...

The Organisation for Economic Co-operation and Development (OECD), through its Working Party on Biotechnology, undertook a project on “Healthy Ageing and Biomedical Innovation for Dementia and Alzheimer’s disease”. The project was conducted under Output Result 2.1 of the WPB Programme of...